Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

What is the optimal number of chemo cycles for advanced urothelial carcinoma?

30 Nov 2018

It appears that four cycles of platinum-based, first-line chemotherapy are tolerable and do not significantly compromise the survival of patients with metastatic urothelial carcinoma, suggests a study.

A total of 1,020 patients were included, of whom 338 and 134 received cisplatin or carboplatin, respectively. Three to five cycles (median, four) of chemotherapy were given to 157 patients, while 315 received six to nine cycles (median, six).

Overall survival between the two cycles did not show any significant difference (hazard ratio, 1.02; 95 percent CI, 0.78–1.3; p=0.91). Moreover, there were no significant interactions for the type of platinum (p=0.09) and completed planned chemotherapy (p=0.56).

Limitations of a hypothesis-generating, retrospective analysis applied.

“The omission of excessive cycles may avoid unnecessary cumulative toxicity and facilitate a better transition to second line therapy and investigational switch maintenance therapy strategies,” the authors said. “These results require prospective validation, but they may impact practice in select patients.”

The RISC (Retrospective International Study of Invasive/Advanced Cancer of the Urothelium) database was accessed to identify patients in this study. The authors performed Cox multiple regression analysis, controlling for recognized prognostic factors, to examine the association between the number of cycles of chemotherapy and overall survival.

Patients who received fewer than three or more than nine platinum chemotherapy cycles were excluded to reduce confounding factors. Overall survival for three to five and six to nine cycles was the primary endpoint, using 6-month landmark analysis when 281 death events occurred.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.